Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595
Nicola Sgherza, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa, Francesca Fazio, Anna Mele, Bernardo Rossini, Giulia Palazzo, Daniela Roccotelli, Simona Rasola
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMultiple Myeloma Research and Treatments · HIV/AIDS drug development and treatment · Protein Degradation and Inhibitors
Error in Surname
In the original publication [1], there surname of author Roberta Della Pepa should be Della Pepa.
Error in Table
In the original publication [1], there was a mistake in Table 1 as published. The number of patients with normal and elevated LDH is 59 (72) and 23 (28), respectively (instead of 23 (28) and 59 (72)). The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Sgherza N. Battisti O. Curci P. Conticello C. Palmieri S. Derudas D. Germano C. Martino E.A. Mele G. Della Pepa R. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (Isa Kd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study Pharmaceuticals 20251859510.3390/ph 1804059540284030 PMC 12030129 · doi ↗ · pubmed ↗